CASI Pharmaceuticals, Inc.

CASI

NASDAQ · Biotechnology

$0.15

At close - Jun 20, 4:00 PM EDT - USD

Market Cap$2M

P/E-0.1x

52W High$2.13

Volume7.9K

VCP Research Verdict2025Q3

Persistent Operating Losses Threaten Corporate Solvency

CASI Pharmaceuticals faces a critical inflection point as its commercial model struggles to gain traction in the Chinese oncology market, evidenced by a 60.5% year-over-year revenue decline in 2025Q3. The company's reliance on in-licensed assets has failed to ...

GrowthContracting

ProfitabilityNegative

ValuationReview

TechnicalsWeak

Explore valuation models

MARKET ACTION

CASI price & volume

Price trend, volume and key moving averages

Launch Terminal

Loading chart...

Market performance

Price History →

Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return

CASI-81.80%

S&P 500 (^GSPC)+12.39%

1-Year Return

CASI-90.13%

S&P 500 (^GSPC)+15.77%

3-Year Return

CASI-92.50%

S&P 500 (^GSPC)+82.10%

5-Year Return

CASI-98.81%

S&P 500 (^GSPC)+71.71%

Growth & profitability

Annual revenue & EPS trend

Revenue

$29M-15.8% YoY

Net income

-$39M-45.7% YoY

Free cash flow

-$29M-32.7% YoY

Operating margin

-138.8%-64.8 pts YoY

ROIC (TTM)-153%

Avg ROIC 5Y-

ROE (TTM)-301.8%

Piotroski Score2 / 9

Financial Statements →

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

MARKET COVERAGE

Latest News

1 Stories

Accesswire·Aug 14, 2026

CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results

SOUTH SAN FRANCISCO, CA / ACCESS Newswire / August 14, 2026 / CASI Pharmaceuticals, Inc. (OTCQB:CASIF), a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with antibody-mediated rejection (AMR) in organ transplant and various autoimmune diseases, today reported business and financial results for the first half year ended June 30, 2026. "We remained focused on advancing the development of our lead program, CID-103," said Dr. Wei-Wu He, Executive Chairman and Principal Executive Officer of CASI.

Filtered for CASI Pharmaceuticals, Inc.More Headlines

Compare before deciding

Benchmark CASI against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for CASI Pharmaceuticals, Inc. (CASI)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
CASICASI Pharmaceuticals, Inc.Current	$0.15	$2.33M	-0.06	-15.77%	-137.57%	-301.8%	31.1%
ZLABZai Lab Limited	$26.44	$2.99B	-16.53	15.33%	-41.86%	-27.43%	—
LEGNLegend Biotech Corporation	$18.45	$3.41B	-11.53	64.04%	-7.21%	-8.7%	—
ZYMEZymeworks Inc.	$27.50	$2.02B	-25.46	38.87%	-138685.11%	-222.5%	—
CANCanaan Inc.	$0.39	$279.43M	-0.86	96.69%	-67.79%	-80.25%	—
HALOHalozyme Therapeutics, Inc.	$112.44	$13.34B	43.92	37.55%	24.86%	180.63%	—

Compare CASI vs Peers

CASI Pharmaceuticals, Inc. (CASI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ZLAB

Most directly comparable listed peer for CASI.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare CASI against a more recognizable public peer.

Peer Set

Compare Top 5

vs ZLAB, LEGN, ZYME, CAN

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

CASI SEC Filings & Documents

CASI Pharmaceuticals, Inc. (CASI) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Mar 21, 2023·SEC

Material company update

Jan 31, 2023·SEC

Material company update

Nov 14, 2022·SEC

10-K Annual Reports

FY 2022

Mar 28, 2022·SEC

10-Q Quarterly Reports

FY 2022

Nov 14, 2022·SEC

FY 2022

Aug 12, 2022·SEC

FY 2022

May 12, 2022·SEC

Get notified when CASI posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

CASI Frequently Asked Questions

CASI Pharmaceuticals, Inc. (CASI) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is CASI Pharmaceuticals, Inc.'s revenue?

CASI Pharmaceuticals, Inc. (CASI) reported $26.8M in revenue for fiscal year 2024. This represents a 3629% increase from $0.7M in 1995.

How fast is CASI Pharmaceuticals, Inc. growing?

CASI Pharmaceuticals, Inc. (CASI) saw revenue decline by 15.8% over the past year.

Is CASI profitable?

CASI Pharmaceuticals, Inc. (CASI) reported a net loss of $49.4M for fiscal year 2024.

Dividend & Returns

Does CASI pay dividends?

Yes, CASI Pharmaceuticals, Inc. (CASI) pays a dividend with a yield of 31.10%. This makes it attractive for income-focused investors.

What is CASI's return on equity?

CASI Pharmaceuticals, Inc. (CASI) has a return on equity (ROE) of -301.8%. Negative ROE indicates the company is unprofitable.

What is CASI Pharmaceuticals, Inc.'s free cash flow?

CASI Pharmaceuticals, Inc. (CASI) had negative free cash flow of $29.5M in fiscal year 2024, likely due to heavy capital investments.

What if you invested $1,000 in CASI back in 1995?

Total return calculator · dividends reinvested · 31+ years of data

See returns →

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

CASICASI Pharmaceuticals, Inc.Current

$0.15

$2.33M

-0.06

-15.77%

-137.57%

-301.8%

31.1%

ZLABZai Lab Limited

$26.44

$2.99B

-16.53

15.33%

-41.86%

-27.43%

—

LEGNLegend Biotech Corporation

$18.45

$3.41B

-11.53

64.04%

-7.21%

-8.7%

—

ZYMEZymeworks Inc.

$27.50

$2.02B

-25.46

38.87%

-138685.11%

-222.5%

—

CANCanaan Inc.

$0.39

$279.43M

-0.86

96.69%

-67.79%

-80.25%

—

HALOHalozyme Therapeutics, Inc.

$112.44

$13.34B

43.92

37.55%

24.86%

180.63%

—